Receptor tyrosine kinase targeting in glioblastoma: Performance, limitations and future approaches

35Citations
Citations of this article
42Readers
Mendeley users who have this article in their library.

Abstract

From all central nervous system tumors, gliomas are the most common. Nowadays, researchers are looking for more efficient treatments for these tumors, as well as ways for early diagnosis. Receptor tyrosine kinases (RTKs) are major targets for oncology and the development of small-molecule RTK inhibitors has been proven successful in cancer treatment. Mutations or aberrant activation of the RTKs and their intracellular signaling pathways are linked to several malignant diseases, including glioblastoma. The progress in the understanding of malignant glioma evolution has led to RTK targeted therapies with high capacity to improve the therapeutic response while reducing toxicity. In this review, we present the most important RTKs (i.e. EGFR, IGFR, PDGFR and VEGFR) currently used for developing cancer therapeutics together with the potential of RTK-related drugs in glioblastoma treatment. Also, we focus on some therapeutic agents that are currently at different stages of research or even in clinical phases and proved to be suitable as re-purposing candidates for glioblastoma treatment.

Author supplied keywords

Cite

CITATION STYLE

APA

Alexandru, O., Horescu, C., Sevastre, A. S., Cioc, C. E., Baloi, C., Oprita, A., & Dricu, A. (2020). Receptor tyrosine kinase targeting in glioblastoma: Performance, limitations and future approaches. Wspolczesna Onkologia. Termedia Publishing House Ltd. https://doi.org/10.5114/wo.2020.94726

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free